The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III trials, including the IMPACT (IMunotherapy for Prostate Adeno Carcinoma Treatment) Trial that led to the eventual approval of Provenge by the FDA.
The two specific abstracts that were of personal interest were:
1- An analysis which evaluated the survival benefit associated with Provenge in African-American men who participated in the three phase III studies. Among the 737 men with metastatic castrate-resistant advanced prostate cancer, 488 were randomized to receive Provenge (African-American, 33; Caucasian, 437; other races, 18) and 249 were randomized to the control arm (African-American, 10; Caucasian, 229; other races, 10). They then performed a Cox proportional hazards regression analysis was used to assess the treatment effect on overall survival in all randomized patients and the African-American subpopulation.
The results of the African-American subgroup suggested a positive treatment effect (HR=0.288